- H.R. 10171August 27, 2026
- H.R. 10156August 27, 2026
- H.R. 10172August 27, 2026
- H.R. 10160August 27, 2026
- H.R. 10181August 27, 2026
- H.R. 10176August 27, 2026
- H.Res. 1496August 27, 2026
- H.R. 10164August 27, 2026
- H.R. 10170August 27, 2026
- H.Res. 1494August 27, 2026
- H.R. 10163August 27, 2026
- H.R. 10157August 27, 2026
- Administration
- Agriculture
- Agriculture, Nutrition, And Forestry
- Appropriations
- Armed Services
- Banking, Housing, And Urban Affairs
- Budget
- Commerce, Science, And Transportation
- Education and Workforce
- Energy And Commerce
- Energy And Natural Resources
- Environment And Public Works
- Ethics
- Finance
- Financial Services
- Foreign Affairs
- Foreign Relations
- Health, Education, Labor, And Pensions
- Homeland Security
- Homeland Security And Governmental Affa…
- Indian Affairs
- Indian and Insular Affairs
- Intelligence
- Judiciary
- Natural Resources
- Oversight And Government Reform
- Permanent Select Intelligence
- Rules
- Rules And Administration
- Science, Space, And Technology
- Select Intelligence
- Small Business
- Small Business And Entrepreneurship
- Subcommittee on Aviation
- Subcommittee on Border Security and Enf…
- Subcommittee on Coast Guard and Maritim…
- Subcommittee on Commodity Markets, Digi…
- Subcommittee on Conservation, Research,…
- Subcommittee on Counterterrorism and In…
- Subcommittee on Cybersecurity and Infra…
- Subcommittee on Disability Assistance a…
- Subcommittee on Economic Development, P…
- Subcommittee on Economic Opportunity
- Subcommittee on Emergency Management an…
- Subcommittee on Energy and Mineral Reso…
- Subcommittee on Federal Lands
- Subcommittee on Forestry and Horticultu…
- Subcommittee on General Farm Commoditie…
- Subcommittee on Health
- Subcommittee on Highways and Transit
- Subcommittee on Livestock, Dairy, and P…
- Subcommittee on Nutrition and Foreign A…
- Subcommittee on Oversight and Investiga…
- Subcommittee on Oversight, Investigatio…
- Subcommittee on Railroads, Pipelines, a…
- Subcommittee on Transportation and Mari…
- Subcommittee on Water Resources and Env…
- Subcommittee on Water, Wildlife and Fis…
- Transportation And Infrastructure
- Veterans' Affairs
- Ways And Means

H.R. 7970
U.S. House•In House Committee
Summary
H.R. 7970, the STOP Nitazenes Act, was introduced in the House on Mar 18, 2026 by Rep. Robert Latta (R) with 10 co-sponsors. It last saw action on Jul 21, 2026: Ordered to be Reported in the Nature of a Substitute by the Yeas and Nays: 28 - 21.
Record
Text
H.R. 7970 has 10 co-sponsors.
hb7970/introduced-in-house.txt119 HR 7970 IH: Strengthening Tools to Outlaw Poisonous Nitazenes ActU.S. House of Representatives2026-03-18text/xmlENPursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.I 119th CONGRESS 2d Session H. R. 7970 IN THE HOUSE OF REPRESENTATIVES March 18, 2026 Mr. Latta introduced the following bill; which was referred to the Committee on Energy and Commerce , and in addition to the Committee on the Judiciary , for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned A BILLTo amend the Controlled Substances Act to permanently schedule 2-benzylbenzimidazole opioids (commonly referred to as nitazenes) as Schedule 1 controlled substances, and for other purposes.1.Short titleThis Act may be cited as the Strengthening Tools to Outlaw Poisonous Nitazenes Act or the STOP Nitazenes Act .2.Class I scheduling of nitazenes(a)In generalSection 202(c) of the Controlled Substances Act ( 21 U.S.C. 812(c) ) is amended by adding at the end of Schedule I the following:(f)(1)Unless specifically exempted or unless listed in another schedule, any material, compound, mixture, or preparation that contains—(A)any quantity of a 2-benzylbenzimidazole opioid; or(B)the salts, isomers, and salts of isomers of a 2-benzylbenzimidazole opioid.(2)For purposes of paragraph (1), the term ‘2-benzylbenzimidazole opioid’ includes the following:(A)A substance that is structurally related to 2-benzylbenzimidazole with the following modifications:(i)At the 1-position, substitution with an alkyl linker connected to a substituted amine group containing hydrogen, alkyl, alkenyl, or a heteroaryl group, such as a morphilino, pyrrolidino, or piperidinyl group, whether or not further substituted.(ii)At the 2-position—(I)replacement of the alkyl portion of the benzyl group with a substituted or unsubstituted alkyl, alkoxy, carbamates group, nitrogen, sulfur, or oxygen atom; or(II)replacement of the phenyl portion of the benzyl group with an aryl or heteroaryl group.(iii)Substitution on the phenyl portion of the benzimidazole ring with a hydrogen atom, halogen, nitro, cyano, substituted or unsubstituted amide, amine, alkyl, alkoxy, aryl, or heteroaryl group.(iv)At the 6-position, substitution with hydrogen, nitro, trifluoromethyl, methoxy, trifluoromethoxy, cyano, and halogen group.(B)A substance that exhibits agonist activity at the mu-opioid receptor.(C)Etonitazene, clonitazene, metonitazene, isotonitazene, protonitazene, butonitazene, etodesnitazene, flunitazene, N-pyrrolidino etonitazene, N-desethyl isotonitazene, and N-piperidinyl etonitazene.(3)The Attorney General may by order publish in the Federal Register a list of substances that satisfy the definition of the term 2-benzyl benzimidazole opioid in paragraph (2)..(b)Removal of temporary statusAny substance included in the amendment made by subsection (a) that was temporarily scheduled under section 201(h) of the Controlled Substances Act ( 21 U.S.C. 811(h) ) shall be deemed permanently scheduled and subject to the requirements of Schedule I of section 202(c) of that Act ( 21 U.S.C. 812(c) ) as of the date of enactment of this Act.3.Rulemaking(a)Interim final ruleThe Attorney General—(1)shall, not later than 1 year after the date of enactment of this Act, issue rules to implement this Act, including the amendments made by this Act; and(2)may issue the rules under paragraph (1) as an interim final rule.(b)Procedure for final rule(1)Effectiveness of interim final rulesA rule issued by the Attorney General as an interim final rule under subsection (a) shall become immediately effective as an interim final rule without requiring the Attorney General to demonstrate good cause therefor, notwithstanding subparagraph (B) of section 553(b) of title 5, United States Code.(2)Opportunity for comment and hearingAn interim final rule issued under subsection (a) shall give interested persons the opportunity to comment and to request a hearing.(3)Final ruleAfter the conclusion of proceedings under paragraph (2), the Attorney General shall issue a final rule to implement this Act, including the amendments made by this Act, in accordance with section 553 of title 5, United States Code.
Tracker
The tracker indicates the progress of this legislation as it moves through the legislative process.
- Introduced2026-03-18
- Passed House
- Passed Senate
- Conference
- To President
- Became Law
To amend the Controlled Substances Act to permanently schedule 2-benzylbenzimidazole opioids (commonly referred to as nitazenes) as Schedule 1 controlled substances, and for other purposes.
Sponsors
Rep. Robert Latta (R) sponsors H.R. 7970, and 10 members have co-sponsored it.

Rep. · R–OH-5 · Sponsor
Introduced Mar 18, 2026

Rep. · D–VA-7 · Co-sponsor
Joined Mar 26, 2026

Rep. · R–WA-5 · Co-sponsor
Joined Mar 27, 2026

Rep. · R–OH-14 · Co-sponsor
Joined Mar 27, 2026

Rep. · R–KS-1 · Co-sponsor
Joined Apr 9, 2026

Rep. · R–IN-4 · Co-sponsor
Joined Apr 27, 2026

Rep. · R–TX-11 · Co-sponsor
Joined Apr 27, 2026

Rep. · R–NC-6 · Co-sponsor
Joined May 13, 2026

Rep. · R–TX-12 · Co-sponsor
Joined Jun 30, 2026

Rep. · R–NC-14 · Co-sponsor
Joined Jul 13, 2026
Committees
H.R. 7970 went before 3 committees: Energy and Commerce, Health Subcommittee and Judiciary.
Actions
H.R. 7970 has taken 8 actions since Mar 18, 2026, the latest on Jul 21, 2026.
| Chamber | Action | |||
|---|---|---|---|---|
Jul 21, 2026 | House | Ordered to be Reported in the Nature of a Substitute by the Yeas and Nays: 28 - 21.Energy and Commerce Committee | ||
Jul 21, 2026 | House | Committee Consideration and Mark-up Session HeldEnergy and Commerce Committee | ||
Jul 20, 2026 | House | Committee Consideration and Mark-up Session HeldEnergy and Commerce Committee | ||
Jun 25, 2026 | House | Subcommittee Consideration and Mark-up Session HeldHealth Subcommittee | ||
Jun 25, 2026 | House | Forwarded by Subcommittee to Full Committee by Voice Vote.Health Subcommittee |
Votes
H.R. 7970 has not gone to a roll call.
Titles
H.R. 7970 goes by 4 titles, 2 of them short titles.
- STOP Nitazenes Act — Display Title
- STOP Nitazenes Act — Short Title(s) as Introduced
- Strengthening Tools to Outlaw Poisonous Nitazenes Act — Short Title(s) as Introduced
- To amend the Controlled Substances Act to permanently schedule 2-benzylbenzimidazole opioids (commonly referred to as nitazenes) as Schedule 1 controlled substances, and for other purposes. — Official Title as Introduced
Lobbying
6 clients hired 6 firms and 44 registered lobbyists who named H.R. 7970 in 10 quarterly filings, 2026. Reported under the Lobbying Disclosure Act; a filing’s income covers everything its registrant worked that quarter, so the amounts below are the filings’, not this bill’s.
Filed under Law Enforcement/Crime/Criminal Justice, Civil Rights/Civil Liberties, Health Issues, Budget/Appropriations, Alcohol and Drug Abuse, Constitution, Education, Immigration.
Clients
Who paid to be heard, by how many filings named the bill.
| Client | Business | State | Firms | Filings | Reported |
|---|---|---|---|---|---|
| AMERICAN MEDICAL ASSOCIATION | — | District of Columbia | 1 | 2 | — |
| DRUG POLICY ALLIANCE | — | New York | 1 | 2 | — |
| DUE PROCESS INSTITUTE | — | District of Columbia | 1 | 2 | — |
| NATIONAL ASSOCIATION OF CRIMINAL DEFENSE LAWYERS (NACDL) | — | District of Columbia | 1 | 2 | — |
| SOUTHEAST GEORGIA HOSPITAL SYSTEM | Hospital System, three hospitals and a nursing home | Georgia | 1 | 1 | $24K |
| AMERICAN CIVIL LIBERTIES UNION | — | District of Columbia | 1 | 1 | — |
Firms
Registrants who filed on the bill, by filings.
| Registrant | Clients | Filings | Reported |
|---|---|---|---|
| AMERICAN MEDICAL ASSOCIATION | 1 | 2 | — |
| DRUG POLICY ALLIANCE | 1 | 2 | — |
| DUE PROCESS INSTITUTE | 1 | 2 | — |
| NATIONAL ASSOCIATION OF CRIMINAL DEFENSE LAWYERS (NACDL) | 1 | 2 | — |
| AMERICAN CIVIL LIBERTIES UNION | 1 | 1 | — |
| CAROL G HOLLADAY & ASSOCIATES | 1 | 1 | $24K |
Lobbyists
Named on the filings that cite the bill. The 20 named most often, of 44.
| Lobbyist | Firms | Clients | Filings |
|---|---|---|---|
| ALEXIS PIERCE | 1 | 1 | 2 |
| ANDREW WANKUM | 1 | 1 | 2 |
| ANGELA FRANKLIN | 1 | 1 | 2 |
| ASHLEY DELOSH | 1 | 1 | 2 |
| BRYAN HULL | 1 | 1 | 2 |
| CHRISTOPHER SHERIN | 1 | 1 | 2 |
| DANA LICHTENBERG | 1 | 1 | 2 |
| DANIEL FISHBEIN | 1 | 1 | 2 |
| HANNA SHARIF-KAZEMI | 1 | 1 | 2 |
| JASON MARINO | 1 | 1 | 2 |
| JASON PYE | 1 | 1 | 2 |
| JEFFREY COUGHLIN | 1 | 1 | 2 |
| JENNIFER BROWN | 1 | 1 | 2 |
| KATHERINE DAPPER | 1 | 1 | 2 |
| KORYN RUBIN | 1 | 1 | 2 |
| KYLE O'DOWD | 1 | 1 | 2 |
| LINDSEY BRILL | 1 | 1 | 2 |
| LISA MYERS | 1 | 1 | 2 |
| MARGARET GARIKES | 1 | 1 | 2 |
| MARITZA PEREZ MEDINA | 1 | 1 | 2 |
Filings
The documents themselves, on the Senate’s Lobbying Disclosure site, largest reported first.
| Client | Registrant | Period | Reported | Document |
|---|---|---|---|---|
| AMERICAN MEDICAL ASSOCIATION | AMERICAN MEDICAL ASSOCIATION | 2026 second_quarter | $5.1M | 2nd Quarter - Amendme… |
| AMERICAN CIVIL LIBERTIES UNION | AMERICAN CIVIL LIBERTIES UNION | 2026 second_quarter | $670K | 2nd Quarter - Report |
| AMERICAN MEDICAL ASSOCIATION | AMERICAN MEDICAL ASSOCIATION | 2026 second_quarter | $513K | 2nd Quarter - Report |
| SOUTHEAST GEORGIA HOSPITAL SYSTEM | CAROL G HOLLADAY & ASSOCIATES | 2026 second_quarter | $24K | 2nd Quarter - Report |
| DRUG POLICY ALLIANCE | DRUG POLICY ALLIANCE | 2026 second_quarter | $18.6K | 2nd Quarter - Report |
| DUE PROCESS INSTITUTE | DUE PROCESS INSTITUTE | 2026 second_quarter | $15K | 2nd Quarter - Report |
| NATIONAL ASSOCIATION OF CRIMINAL DEFENSE LAWYERS (NACDL) | NATIONAL ASSOCIATION OF CRIMINAL DEFENSE LAWYERS (NACDL) | 2026 second_quarter | $15K | 2nd Quarter - Report |
| DUE PROCESS INSTITUTE | DUE PROCESS INSTITUTE | 2026 first_quarter | $15K | 1st Quarter - Report |
| NATIONAL ASSOCIATION OF CRIMINAL DEFENSE LAWYERS (NACDL) | NATIONAL ASSOCIATION OF CRIMINAL DEFENSE LAWYERS (NACDL) | 2026 first_quarter | $15K | 1st Quarter - Report |
| DRUG POLICY ALLIANCE | DRUG POLICY ALLIANCE | 2026 first_quarter | — | 1st Quarter - Report |
Classification
The Congressional Research Service files H.R. 7970 under Crime and Law Enforcement, one of its 31 policy areas, and gives it 3 legislative subjects.
CRS Subjects
CRS assigns every bill one policy area from its 31; H.R. 7970’s is Crime and Law Enforcement.
hr7970/policy-areas.txtLegislative Subjects
H.R. 7970 carries 3 of CRS’s legislative subjects, from Administrative law and regulatory procedures to Drug trafficking and controlled substances.
hr7970/subjects.txtConstitutional authority
The clause the sponsor cites as Congress’s power to enact H.R. 7970, as entered in the Congressional Record.
[Congressional Record Volume 172, Number 49 (Wednesday, March 18, 2026)][House]From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]By Mr. LATTA:H.R. 7970.Congress has the power to enact this legislation pursuantto the following:Article I, Section 8, Clause 3: Congress shall have thepower . . . ``to regulate Commerce with foreign Nations, andamong the several States, and with the Indian tribes.''[Page H2597]
Source: congress.gov · legiscan.com